Abstract:Encoded by PTPN11 , the Src-homology 2 domain-containing phosphatase 2 (SHP2) integrates signals from various membrane-bound receptors such as receptor tyrosine kinases (RTKs), cytokine and integrin receptors and thereby promotes cell survival and proliferation. Activating mutations in the PTPN11 gene may trigger signaling pathways leading to the development of hematological malignancies, but are rarely found in solid tumors. Yet, aberrant SHP2 expression or activation has implications in the development, progression and metastasis of many solid tumor entities. SHP2 is involved in multiple signaling cascades, including the RAS-RAF-MEK-ERK-, PI3K-AKT-, JAK-STAT- and PD-L1/PD-1- pathways. Although not mutated, activation or functional requirement of SHP2 appears to play a relevant and context-dependent dichotomous role. This mostly tumor-promoting and infrequently tumor-suppressive role exists in many cancers such as gastrointestinal tumors, pancreatic, liver and lung cancer, gynecological entities, head and neck cancers, prostate cancer, glioblastoma and melanoma. Recent studies have identified SHP2 as a potential biomarker for the prognosis of some solid tumors. Based on promising preclinical work and the advent of orally available allosteric SHP2-inhibitors early clinical trials are currently investigating SHP2-directed approaches in various solid tumors, either as a single agent or in combination regimes. We here provide a brief overview of the molecular functions of SHP2 and collate current knowledge with regard to the significance of SHP2 expression and function in different solid tumor entities, including cells in their microenvironment, immune escape and therapy resistance. In the context of the present landscape of clinical trials with allosteric SHP2-inhibitors we discuss the multitude of opportunities but also limitations of a strategy targeting this non-receptor protein tyrosine phosphatase for treatment of solid tumors.

Targeting SHP2 As a Promising Strategy for Cancer Immunotherapy

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches

SUN2: A potential therapeutic target in cancer (Review)

Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors

Roles of protein tyrosine phosphatase SHP2 in lung cancer

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade

Loss of SHP-2 Activity in CD4+ T Cells Promotes Melanoma Progression and Metastasis

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy

Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull's eye for targeted therapy?

Functions of Shp2 in cancer

A patent review of SHP2 allosteric inhibitors (2018-present)

Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders

Allosteric inhibition reveals SHP2-mediated tumor immunosuppression in colon cancer by single-cell transcriptomics

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop

Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment

Strategy for Leukemia Treatment Targeting SHP-1,2 and SHIP

Cross the Undruggable Barrier, the Development of SHP2 Inhibitors: from Catalytic Site Inhibitors to Allosteric Inhibitors

A small molecule inhibitor targeting SHP2 mutations for the lung carcinoma